Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Dynamic Epigenetic Changes during a Relapse and Recovery Cycle in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

A.M. Helliwell, P.A. Stockwell, C.D. Edgar, A. Chatterjee, View ORCID ProfileW.P. Tate
doi: https://doi.org/10.1101/2022.02.24.22270912
A.M. Helliwell
1Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.A. Stockwell
2Department of Pathology, University of Otago, Dunedin 9016, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C.D. Edgar
1Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Chatterjee
2Department of Pathology, University of Otago, Dunedin 9016, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W.P. Tate
1Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for W.P. Tate
  • For correspondence: warren.tate@otago.ac.nz
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex disease with variable severity throughout the ongoing illness. Patients experience relapses where symptoms increase in severity, leaving them with a marked reduction in quality of life. Previous work has investigated molecular differences between ME/CFS patients and healthy controls, but the dynamic changes specific to each individual patient are unknown. Precision medicine can determine how each patient responds individually during variations in their long-term illness. We apply precision medicine here to map genomic changes in two selected ME/CFS patients through a relapse recovery cycle.

Results DNA was isolated from Peripheral Blood Mononuclear Cells (PBMCs) from two patients and a healthy age/gender matched control in a longitudinal study to capture a patient relapse. Reduced representation DNA methylation sequencing profiles were obtained from each time point spanning the relapse recovery cycle. Both patients throughout the time course showed a significantly larger methylome variability (10-20 fold) compared with the control. During the relapse changes in the methylome profiles of the two patients were detected in regulatory-active regions of the genome that were associated respectively with 157 and 127 downstream genes, indicating disturbed metabolic, immune and inflammatory functions occurring during the relapse.

Conclusions Severe health relapses in ME/CFS patients result in functionally important changes in their DNA methylomes that, while differing among patients, lead to similar compromised physiology. DNA methylation that is a signature of disease variability in ongoing ME/CFS may have practical applications for strategies to decrease relapse frequency.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by a grant from the Healthcare Otago Charitable Trust, from the Associated New Zealand Myalgic Encephalomyelitis Society (ANZMES), and from generous private donations from ME/CFS families.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study conforms to the ethics approval 17/STH/188 for ME/CFS patient studies from the Southern Health and Disability Ethics Committee of New Zealand. General consultation with Ngai Tahu Research Committee of the University of Otago was carried out before the beginning of this research

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* joint senior authors

Data Availability

All datasets generated and analysed during this current study are available in the GEO database NCBI (GSE166592)

  • List of abbreviations

    CpG
    5’: Cytosine-3’phosphate-5’Guanosine-3’
    iVMF
    Intra-individual variably methylated fragment
    ME/CFS
    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
    DMAP
    Differential methylation analysis program
    PBMC
    Peripheral blood mononuclear cells
    RRBS
    Reduced representation bisulfite sequencing
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted February 26, 2022.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Dynamic Epigenetic Changes during a Relapse and Recovery Cycle in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Dynamic Epigenetic Changes during a Relapse and Recovery Cycle in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
    A.M. Helliwell, P.A. Stockwell, C.D. Edgar, A. Chatterjee, W.P. Tate
    medRxiv 2022.02.24.22270912; doi: https://doi.org/10.1101/2022.02.24.22270912
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Dynamic Epigenetic Changes during a Relapse and Recovery Cycle in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
    A.M. Helliwell, P.A. Stockwell, C.D. Edgar, A. Chatterjee, W.P. Tate
    medRxiv 2022.02.24.22270912; doi: https://doi.org/10.1101/2022.02.24.22270912

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Genetic and Genomic Medicine
    Subject Areas
    All Articles
    • Addiction Medicine (179)
    • Allergy and Immunology (432)
    • Anesthesia (99)
    • Cardiovascular Medicine (946)
    • Dentistry and Oral Medicine (178)
    • Dermatology (109)
    • Emergency Medicine (260)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
    • Epidemiology (8977)
    • Forensic Medicine (4)
    • Gastroenterology (419)
    • Genetic and Genomic Medicine (1943)
    • Geriatric Medicine (190)
    • Health Economics (401)
    • Health Informatics (1324)
    • Health Policy (657)
    • Health Systems and Quality Improvement (518)
    • Hematology (212)
    • HIV/AIDS (417)
    • Infectious Diseases (except HIV/AIDS) (10787)
    • Intensive Care and Critical Care Medicine (574)
    • Medical Education (200)
    • Medical Ethics (54)
    • Nephrology (222)
    • Neurology (1823)
    • Nursing (109)
    • Nutrition (271)
    • Obstetrics and Gynecology (352)
    • Occupational and Environmental Health (470)
    • Oncology (996)
    • Ophthalmology (297)
    • Orthopedics (111)
    • Otolaryngology (182)
    • Pain Medicine (126)
    • Palliative Medicine (44)
    • Pathology (265)
    • Pediatrics (578)
    • Pharmacology and Therapeutics (275)
    • Primary Care Research (234)
    • Psychiatry and Clinical Psychology (1894)
    • Public and Global Health (4117)
    • Radiology and Imaging (675)
    • Rehabilitation Medicine and Physical Therapy (365)
    • Respiratory Medicine (548)
    • Rheumatology (224)
    • Sexual and Reproductive Health (190)
    • Sports Medicine (177)
    • Surgery (207)
    • Toxicology (39)
    • Transplantation (109)
    • Urology (80)